Document:

<PAGE>   1

                                                                    Exhibit 10.1

                             SECURED PROMISSORY NOTE

                                                                  April 10, 2001

$875,000                                                   Newton, Massachusetts

      FOR VALUE RECEIVED, Nassib G. Chamoun (the "Maker"), promises to pay to
Aspect Medical Systems, Inc. (the "Company"), or order, at the offices of the
Company or at such other place as the holder of this Note may designate, the
principal sum of eight hundred seventy five dollars ($875,000), together with
interest on the unpaid principal balance of this Note from time to time
outstanding at the rate of 5.07% per year until paid in full. Principal and
interest shall be paid as follows:

      -     an amount equal to interest only on the outstanding amount of the
            loan will be paid to the Company on each of April 10, 2002 and April
            10, 2003; and

      -     an amount equal $218,750, plus interest on the outstanding amount of
            the loan will be paid to the Company on each of April 10, 2004, and
            April 10, 2005; and

      -     all outstanding principal and interest on the loan will be paid to
            the Company on April 10, 2006.

      Interest on this Note shall be computed on the basis of a year of 365 days
for the actual number of days elapsed, compounded annually. All payments by the
Maker under this Note shall be in immediately available funds.

      Payment of this Note is secured by a security interest in certain property
of the Maker (the "Collateral") pursuant to a pledge agreement of even date
herewith between the Maker and the Company (the "Pledge Agreement").

      This Note shall become immediately due and payable without notice or
demand upon the occurrence at any time of any of the following events of default
(individually, "an Event of Default" and collectively, "Events of Default"):

      (1)   default in the payment when due of any principal, premium or
            interest under this Note;

      (2)   the occurrence of any event of default under the Pledge Agreement;

      (3)   the occurrence of the termination or other cessation of the Maker's
            full-time employment at Aspect, for any reason whether by the Maker
            or by Aspect;

      (4)   the institution against the Maker or any indorser or guarantor of
            this Note of any proceedings under the United States Bankruptcy Code
            or any other federal or state bankruptcy, reorganization,
            receivership, insolvency or other similar law affecting

<PAGE>   2

            the rights of creditors generally, which proceeding is not dismissed
            within thirty (30) days of filing; or

      (5)   the institution by the Maker or any indorser or guarantor of this
            Note of any proceedings under the United States Bankruptcy Code or
            any other federal or state bankruptcy, reorganization, receivership,
            insolvency or other similar law affecting the rights of creditors
            generally or the making by the Maker or any indorser or guarantor of
            this Note of a composition or an assignment or trust mortgage for
            the benefit of creditors.

      Upon the occurrence of an Event of Default, the holder shall have then, or
at any time thereafter, all of the rights and remedies afforded by the Uniform
Commercial Code as from time to time in effect in the Commonwealth of
Massachusetts or afforded by other applicable law.

      Every amount overdue under this Note shall bear interest from and after
the date on which such amount first became overdue at an annual rate which is
two (2) percentage points above the rate per year specified in the first
paragraph of this Note. Such interest on overdue amounts under this Note shall
be payable on demand and shall accrue and be compounded monthly until the
obligation of the Maker with respect to the payment of such interest has been
discharged (whether before or after judgment).

      In no event shall any interest charged, collected or reserved under this
Note exceed the maximum rate then permitted by applicable law and if any such
payment is paid by the Maker, then such excess sum shall be credited by the
holder as a payment of principal.

      All payments by the Maker under this Note shall be made without set-off or
counterclaim and be free and clear and without any deduction or withholding for
any taxes or fees of any nature whatever, unless the obligation to make such
deduction or withholding is imposed by law. The Maker shall pay and save the
holder harmless from all liabilities with respect to or resulting from any delay
or omission to make any such deduction or withholding required by law.

      Whenever any amount is paid under this Note, all or part of the amount
paid may be applied to principal, premium or interest in such order and manner
as shall be determined by the holder in its discretion.

      No reference in this Note to the Pledge Agreement or any guaranty shall
impair the obligation of the Maker, which is absolute and unconditional, to pay
all amounts under this Note strictly in accordance with the terms of this Note.

      The Maker agrees to pay on demand all costs of collection, including
reasonable attorneys' fees, incurred by the holder in enforcing the obligations
of the Maker under this Note.

      No delay or omission on the part of the holder in exercising any right
under this Note or the Security Agreement shall operate as a waiver of such
right or of any other right of such holder, nor shall any delay, omission or
waiver on any one occasion be deemed a bar to or waiver of the same or any other
right on any future occasion. The Maker and every indorser or guarantor of this
Note regardless of the time, order or place of signing waives presentment,
demand, protest and notices of every kind and assents to any extension or
postponement of the

                                      -2-

<PAGE>   3
time of payment or any other indulgence, to any substitution, exchange or
release of collateral, and to the addition or release of any other party or
person primarily or secondarily liable.

      This Note may be prepaid in whole or in part at any time or from time to
time upon ten days' prior written notice with the consent of the holder, with
the giving of such consent to be in the sole discretion of the holder. Any such
prepayment shall be without premium or penalty.

      None of the terms or provisions of this Note may be excluded, modified or
amended except by a written instrument duly executed on behalf of the holder
expressly referring to this Note and setting forth the provision so excluded,
modified or amended.

      All rights and obligations hereunder shall be governed by the laws of the
Commonwealth of Massachusetts and this Note is executed as an instrument under
seal.

ATTEST:                                                 /s/ NASSIB G. CHAMOUN
                                                        ---------------------
                                                        Nassib Chamoun

By: /s/ J. NEAL ARMSTRONG
    ------------------------------
    Title: Vice President and
           Chief Financial Officer

                                      -3-

<PAGE>   4
                                PLEDGE AGREEMENT

            This is a pledge agreement made as of the 10th day of April, 2001
between Nassib G. Chamoun, an individual residing at 6 Cogswell Court, Needham,
Massachusetts 02492 ("Pledgor") and Aspect Medical Systems, Inc., a corporation
organized under the laws of the State of Delaware with its principal office at
141 Needham Street, Newton, Massachusetts 02464-1505 ("Pledgee").

      1.    PLEDGE OF COLLATERAL. Pledgor hereby grants Pledgee a security
interest in the stock and notes identified in Exhibit A, annexed hereto, which
Pledgor has delivered to Pledgee, as well as all other instruments, documents,
stock certificates, money and goods as may be issued to Pledgee or become
issuable to Pledgee by any issuer of such stock or notes from time to time,
whether through delivery by Pledgor or otherwise (the "Collateral").

      2.    OBLIGATIONS SECURED. The security interest in the Collateral granted
hereby secures payment and performance of all debts, loans and liabilities of
Pledgor to Pledgee of every kind and description, whether now existing or
hereafter arising, including but not limited to a promissory note from Pledgor
to Pledgee of even date herewith in the principal amount of $875,000 (the
"Note"), together with all interest, fees, charges and expenses with respect to
any such debt, loan or liability (the "Obligations").

      3.    PLEDGEE'S RIGHTS AND DUTIES WITH RESPECT TO THE COLLATERAL.
Pledgee's only duty with respect to the Collateral shall be to exercise
reasonable care to secure the safe custody thereof. Pledgee shall have the right
but not the obligation to (a) demand, sue for, receive and collect all money or
money damages payable on account of any Collateral, (b) protect, preserve or
assert any other rights of Pledgor or take any other action with respect to the
Collateral, (c) pay any taxes, liens, assessments, insurance premiums or other
charges pertaining to Collateral. Any expenses incurred by Pledgee under the
preceding sentence  Pledgor upon demand, become part of the
Obligations secured by the Collateral and bear interest at the rate provided in
the Note until paid. Pledgee shall be relieved of all responsibility for the
Collateral upon surrendering it to Pledgor.

      4.    PLEDGOR'S WARRANTIES AND INDEMNITY. Pledgor represents, warrants and
covenants (a) that he is and will be the lawful owner of the Collateral, (b)
that the Collateral is and will be fully paid and non-assessable, (c) that the
Collateral is and will remain free and clear of all liens, encumbrances and
security interests other than the security interest granted by Pledgor
hereunder, (d) that Pledgor has the sole right and lawful authority to pledge
the Collateral and otherwise to comply with the provisions hereof, and (e) that
Pledgor has obtained the consent and agreement of the issuer, and all other
persons who have contractual rights or restrictions with respect to the
Collateral, to the pledge, disposition and other rights of Pledgee herein. In
the event that any adverse claim is asserted in respect of the Collateral or any
portion thereof, except such as may result from an act of Pledgee not authorized
hereunder, Pledgor promises and agrees to indemnify Pledgee and hold Pledgee
harmless from and against any losses, liabilities, damages, expenses, costs and
reasonable counsel fees incurred by Pledgee in exercising any right, power or
remedy of Pledgee hereunder or defending, protecting or enforcing the security
interests created hereunder. Any such loss, liability or expense so incurred
shall be paid by

<PAGE>   5
Pledgor upon demand, become part of the Obligations secured by the Collateral
and bear interest at the rate provided in the Note until paid.

      5.    VOTING OF COLLATERAL. While Pledgor is not in default hereunder,
Pledgor may vote stock and other securities pledged as Collateral.

      6.    DIVIDENDS AND OTHER DISTRIBUTIONS. While Pledgor is not in default
hereunder, Pledgor may receive cash dividends, payments of principal and
interest, and other cash distributions payable with respect to Collateral,
PROVIDED, HOWEVER, that Pledgor shall immediately inform Pledgee of the receipt
of any such dividend, payment or other distribution and shall hold the amount
thereof in trust for Pledgee unless and until Pledgee shall in writing release
Pledgor from such trust. Pledgor shall cause all non-cash dividends and
distributions with respect to Collateral to be distributed directly to Pledgee,
to be held by Pledgee as additional Collateral, and if any such distribution is
made to Pledgor, Pledgor shall receive such distribution in trust for Pledgee
and shall immediately transfer it to Pledgee.

      7.    PLEDGOR'S DEFAULT. Pledgor shall be in default hereunder upon the
occurrence of any of the following events:

            (a)   If Pledgor is not paying his debts as they become due, becomes
insolvent, files or has filed against him a petition under any chapter of the
United States Bankruptcy Code, 11 U.S.C. ss. 101 ET SEQ. (or any similar
petition under any insolvency law of any jurisdiction), proposes any
liquidation, composition or financial reorganization with his creditors, makes
an assignment or trust mortgage for the benefit of creditors, or if a receiver,
trustee, custodian or similar agent is appointed or takes possession with
respect to any property or business of Pledgor;

            (b)   If Pledgor dies or becomes incapacitated, or if a conservator
or guardian of Pledgor is appointed, or if Pledgor suffers any other legal
disability;

            (c)   If any lien, encumbrance or adverse claim of any nature
whatsoever is asserted with respect to any Collateral;

            (d)   If any warranty of Pledgor hereunder is or shall become false;

            (e)   If Pledgor fails to fulfill any obligation hereunder;

            (f)   If Pledgor fails to pay or perform any of the Obligations when
such payment of performance is due.

      8.    PLEDGEE'S RIGHTS UPON DEFAULT. Upon the occurrence of any default as
defined in the preceding section, Pledgee may, if Pledgee so elects in its sole
option:

            (a)   at any time and from time to time, sell, assign and deliver
the whole or any part of the Collateral at a sale through a broker in a public
market where securities of the type

                                      -2-
<PAGE>   6
constituting such Collateral are usually traded, without any advertisement,
presentment, demand for performance, protest, notice of protest, notice of
dishonor or any other notice;

            (b)   at any time and from time to time sell, assign and deliver all
or any part of the Collateral, or any interest therein, at any other public or
private sale, for cash, on credit or for other property, for immediate or future
delivery without any assumption of credit risk, and for such price or prices and
on such terms as Pledgee in its absolute discretion may determine, PROVIDED that
(i) at least ten days' notice of the time and place of any such sale shall be
given to Pledgor, and (ii) in the case of any private sale, such notice shall
also contain the minimum terms of the proposed sale;

            (c)   exercise the right to vote, the right to receive cash
dividends and other distributions, and all other rights with respect to the
Collateral as though Pledgee were the absolute owner thereof, whether or not
such rights were retained by Pledgor as against Pledgee before default; and

            (d)   exercise all other rights available to a secured party under
the Uniform Commercial Code and other applicable law.

      9.    APPLICATION OF SALE PROCEEDS. In the event of a sale of Collateral,
the proceeds shall first be applied to the payment of the expenses of the sale,
including brokers' commissions, counsel fees, any taxes or other charges imposed
by law upon the Collateral or the transfer thereof and all other charges paid or
incurred by Pledgee pertaining to the sale; and, second, to satisfy outstanding
Obligations, in the order in which Pledgee elects in its sole discretion; and,
third, the surplus (if any) shall be paid to Pledgor.

      10.   NOTICES. All notices made or required to be made hereunder shall be
sent by United States first class or certified or registered mail, with postage
prepaid, or delivered by hand to Pledgee or to Pledgor at the addresses first
above written. Notice by mail shall be deemed to have been made on the date when
the notice is deposited in the mail.

      11.   HEIRS, SUCCESSORS, ETC. This Pledge Agreement and all of its terms
and provisions shall benefit and bind the heirs, successors, assigns,
transferees, executors and administrators of each of the parties hereto. If this
Pledge Agreement is executed by more than one Pledgor, then (a) "Obligations"
shall include the Obligations of either or both of the Pledgors, (b) Pledgors
shall be in default if any of the events described in Section 7 above takes
place with respect to either Pledgor, (c) any notice required of Pledgee shall
be given to both Pledgors and (d) all Pledgors' obligations, covenants,
warranties and representations hereunder shall be joint and several.

      12.   PLEDGEE'S FORBEARANCE. Any forbearance, failure or delay by Pledgee
in exercising any right, power or remedy hereunder shall not be deemed a waiver
of such right, power or remedy. Any single or partial exercise of any right,
power or remedy of Pledgee shall continue in full force and effect until such
right, power or remedy is specifically waived in writing by Pledgee.

                                      -3-
<PAGE>   7
      EXECUTED under seal at Boston, Massachusetts as of the date first above
written.

PLEDGOR:                                    PLEDGEE:

                                            Aspect Medical Systems, Inc.

/s/ NASSIB G. CHAMOUN                       By: /s/ J. NEAL ARMSTRONG
---------------------------                     --------------------------------
Nassib G. Chamoun                               Name: J. Neal Armstrong
                                                Title: Vice President and Chief
                                                       Financial Officer

                                      -4-
<PAGE>   8

EXHIBIT A

            175,000 shares of the Company's Common Stock, $0.01 par value per
            share

                                      -5-<PAGE>   1
                                  EXHIBIT 10.1

                     FIFTH AMENDMENT TO EMPLOYMENT AGREEMENT

This AMENDMENT TO EMPLOYMENT AGREEMENT (the "Fifth Amendment") made as of
January 1, 2001 between ARIAD Pharmaceuticals, Inc., a Delaware corporation (the
"Company"), and John D. Iuliucci, Ph.D. (the "Employee").

The Company and the Employee have entered into an Employment Agreement dated as
of May 1, 1992, as previously amended (the "Agreement"), and the parties hereto
desire to further amend certain provisions of the Agreement.

NOW, THEREFORE, in consideration of the premises set forth herein and for other
good and valuable consideration, the receipt of which is hereby acknowledged,
the parties hereto agree to further amend the Agreement as follows:

I.     TERM OF EMPLOYMENT. The first sentence of Section 2 is hereby amended to
       read as follows:

       "The term of the Employee's employment under the Agreement is hereby
       extended to December 31, 2003 (the "Term"), unless sooner terminated
       pursuant to Section 4 or 5 of this Agreement; PROVIDED, however, that
       this Agreement shall automatically be renewed for successive one-year
       terms (the Term and, if the period of employment is so renewed, such
       additional period(s) of employment are collectively referred to herein as
       the "Term") unless terminated by written notice given by either party to
       the other at least 90 days prior to the end of the applicable Term."

II.    COMPENSATION. Section 3.1 is hereby replaced and amended in its entirety
       as follows:

       "3.1. As full compensation for all services to be rendered pursuant to
       this Agreement, the Company agrees to pay the Employee, during the Term,
       a salary at the fixed rate of $221,000 per annum during the first year of
       the Term and increased each year thereafter, by amounts, if any, to be
       determined by the Board of Directors of the Company (the "Board") in its
       sole discretion, payable in equal semi-monthly installments, less such
       deductions or amounts to be withheld as shall be required by applicable
       law and regulations."

III.   DEFINITIONS. The definition of the Company's "Field of Interest" in
       Section 14(b) of the Agreement is hereby amended to read as follows:

       The "Company's Field of Interest" is the discovery, development and
       commercialization of (i) pharmaceutical products based on (a)
       intervention in signal transduction pathways and (b) gene and cell
       therapy, and (ii) technologies to regulate genes and proteins. The
       Company's Field of Interest may be changed at any time at the sole
       discretion of the Company.

IV.    This Amendment shall be governed by and construed and enforced in
       accordance with the laws of the Commonwealth of Massachusetts applicable
       to agreements made and to be performed entirely in Massachusetts.

V.     Except as modified by this Fifth Amendment, the Agreement remains in full
       force and effect and unchanged.

                                       1
<PAGE>   2

IN WITNESS WHEREOF, the parties have executed this Fifth Amendment as of the
date first written above.

                                        ARIAD PHARMACEUTICALS, INC.

                                        By: /s/ Harvey J. Berger
                                            ------------------------------------
                                            Harvey J. Berger, M.D.
                                            Chairman and Chief Executive Officer

                                        EMPLOYEE

                                            /s/ John D. Iuliucci
                                            ------------------------------------
                                            John D. Iuliucci, Ph.D.

                                       2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}]]